BeyondSpring (BYSI) to Announce Quarterly Earnings on Wednesday

BeyondSpring (NASDAQ:BYSI) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.54) per share and revenue of $8.7670 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

BeyondSpring (NASDAQ:BYSI) last posted its earnings results on Wednesday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.49.

BeyondSpring Price Performance

BeyondSpring stock opened at $0.99 on Wednesday. The firm has a market capitalization of $40.71 million, a P/E ratio of -7.07 and a beta of 0.48. BeyondSpring has a one year low of $0.99 and a one year high of $2.44. The business has a fifty day moving average price of $1.51 and a 200-day moving average price of $1.54.

Institutional Investors Weigh In On BeyondSpring

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp acquired a new position in BeyondSpring Inc. (NASDAQ:BYSI) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring as of its most recent filing with the Securities & Exchange Commission. 40.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of BeyondSpring in a report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, BeyondSpring presently has a consensus rating of “Sell”.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.